1. Threlfall EJ, et al. Ciprofloxacin-resistant Salmonella typhi and treatment failure. Lancet 1999; 353: 1590–1591.
2. Capoor MR, et al. Salmonella enterica serovar Typhi: molecular analysis of ciprofloxacin decreased susceptibility and resistant isolates from India (2001–2003). Brazilian Journal of Infectious Diseases 2007; 11: 423–425.
3. Levy DD, Sharma B, Cebula TA. Single-nucleotide polymorphism mutation spectra and resistance to quinolones in Salmonella enterica serovar enteritidis with a mutator phenotype. Antimicrobial Agents and Chemotherapy 2004; 48: 2355–2363.
4. Nair S, et al. Molecular analysis of fluoroquinolone-resistant Salmonella Paratyphi A isolate, India. Emerging Infectious Diseases 2006 12: 489–491.
5. Hirose K, et al. DNA sequence analysis of DNA gyrase and DNA topoisomerase in the quinolone resistance determining regions of Salmonella enterica serovar Typhi and serovar Paratyphi A. Antimicrobial Agents and Chemotherapy 2002; 46: 3249–3252.
6. Lindgren PK, Karlsson ASA, Hughes D. Mutation rate and evolution of fluroquinolone resistance in E. coli isolates from patients in urinary tract infections. Antimicrobial Agents and Chemotherapy 2003; 47: 3222–3232.
7. Eaves DJ, et al. Prevalence of mutations within the quinolone resistance determining region of gyrA, gyrB, parC, and parE and association with antibiotic resistance in quinolone-resistance Salmonella enterica. Antimicrobial Agents and Chemotherapy 2004; 48: 4012–4015.
8. Baucheron S, et al. High level resistance to fluoroquinolones linked to mutations in gyr A, par C and par E in Salmonella enterica serovar Schwarzengrund isolated from humans in Taiwan. Antimicrobial Agents and Chemotherapy 2005; 49: 862–863.
9. Ling JM, et al. Mutations in topoisomerase genes of fluoroquinolone resistant Salmonella in Hong Kong. Antimicrobial Agents and Chemotherapy 2003; 47: 3567–3573.
10. Sanders CC. Mechanisms responsible for cross-resistance and dichotomous resistance among quinolones. Clinical Infectious Diseases 2001; 32: 81–88.
11. Crump JA, et al. Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United Stat FoodNet Multicenter Retospective Cohort study. Antimicrobial Agents and Chemotherapy 2008; 52: 1278–1284.
12. Yamane K, et al. New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrobial Agents and Chemotherapy 2007; 51: 3354–3360.
13. Renuka K, et al. High-level ciprofloxacin resistance in Salmonella enterica serovar Typhi in India. Journal of Medical Microbiology 2005; 54: 999–1000.
14. Capoor MR, et al. Enteric fever perspective in India: emergence of high-level ciprofloxacin resistance and rising MIC to cephalosporins. Journal of Medical Microbiology 2007; 56: 1131–1132.
15. Kownhar H, et al. Emergence of nalidixic acid-resistant Salmonella enterica serovar Typhi resistant to ciprofloxacin in India. Journal of Medical Microbiology 2007; 56: 136–137.
16. Adachi T, et al. Fluoroquinolone-resistant Salmonella enterica serovar Paratyphi A. Emerging Infectious Diseases 2005; 11: 172–174.
17. Saha SK, et al. Molecular basis of resistance displayed by highly-ciprofloxacin resistant Salmonella enterica serovar Typhi in Bangladesh. Journal of Clinical Microbiology 2006; 44: 3811–3813.
18. Gaind R, et al. Molecular characterization of ciprofloxacin-resistant Salmonella enterica serovar Typhi and S. Paratyphi A causing enteric fever in India. Journal of Antimicrobial Chemotherapy 2006; 58: 1139–1144.
19. Old DC. Salmonella. In: Collee JG, Fraser AG, Marmion BP, Simmons A eds. Mackie and McCartney Practical Medical Microbiology, 14th edn. New York: Churchill Livingstone, 1996, pp. 385–404.
20. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI document (M100-S16), p. 26. Clinical and Laboratory Standards Institute, 2007. Wayne, Pennsylvania.
21. Giraud E, et al. Comparative study of animal isolates and experimental in vitro- and in vivo-selected mutants of Salmonella spp. suggest a counterselection of highly fluoroquinolone-resistant strains in the field. Antimicrobial Agents and Chemotherapy 1999; 43: 2131–2037.
22. Wang M, et al. Plasmid-mediated Quinolone resistance in clinical isolated in clinical isolates of Escherichia coli from Shanghai, China. Antimicrobial Agents and Chemotherapy 2003; 47: 2242–2248.
23. Mammarei H, et al. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrobial Agents and Chemotherapy 2005; 49: 71–76.
24. Kariuki S, et al. Genotypic analysis of multidrug-resistant Salmonella enterica serovar Typhi, Kenya. Emerging Infectious Diseases 2000; 6: 649–651.
25. Friedman SM, Lu T, Drlica K. Mutation in the DNA Gyrase A gene of Escherichia coli that expands the quinolone resistance-determining region. Antimicrobial Agents and Chemotherapy 2001; 45: 2378–2380.
26. Capoor MR, et al. In vitro activity of azithromycin, newer quinolones and cephalosporins in ciprofloxacin resistant Salmonella causing enteric fever. Journal of Medical Microbiology 2007; 58: 1490–1494.
27. Marano NK, et al. Emerging quinolone and extended spectrum cephalosporin resistant Salmonella in the United States. American Society for Microbiology, 99th General Meeting. Chicago, IL, May 1999.